Royalty Pharma (RPRX) Research & Development (2019 - 2026)
Royalty Pharma (RPRX) posted Research & Development of $39.8 million for Q1 2026, down 21.19% sequentially from $50.5 million in Q4 2025, and down 21.19% YoY from $50.5 million in Q1 2025.
Royalty Pharma (RPRX) Research & Development (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Research & Development for 8 years, with the latest figure at $39.8 million in Q1 2026.
- Quarterly Research & Development fell 21.19% year-over-year to $39.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $390.8 million (up 651.54% YoY) and the FY2025 annual result came in at $452.0 million, up 22500.0% from the prior year.
- Research & Development declined to $39.8 million in Q1 2026 per RPRX's latest filing, from $50.5 million in the prior quarter.
- Over five years, Research & Development peaked at $250.0 million in Q2 2025 and troughed at $500000.0 in Q1 2023.
- A 5-year average of $39.6 million and a median of $25.5 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development tumbled 99.5% in 2023, then jumped 49900.0% in 2025.
- Over 5 years, Research & Development stood at $50.5 million in 2022, then tumbled by 99.01% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then surged by 10000.0% to $50.5 million in 2025, then decreased by 21.19% to $39.8 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $39.8 million, $50.5 million, and $50.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 202.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.90 Mn |
| Mar 31, 2026 | 39.80 Mn |
| Dec 31, 2025 | 50.50 Mn |
| Sep 30, 2025 | 50.50 Mn |
| Jun 30, 2025 | 250.00 Mn |
| Mar 31, 2025 | 50.50 Mn |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 50.50 Mn |
| Jun 30, 2023 | 500,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 50.49 Mn |
| Sep 30, 2022 | 25.50 Mn |
| Jun 30, 2022 | 606,000.00 |
| Mar 31, 2022 | 100.50 Mn |
| Dec 31, 2021 | 103.78 Mn |
| Sep 30, 2021 | 90.50 Mn |